Corcept Therapeutics (CORT) Retained Earnings (2010 - 2026)

Corcept Therapeutics has reported Retained Earnings for 17 years, with the latest figure at $654.6 million in Q2 2026.

• Quarterly Retained Earnings rose 9.21% year-over-year to $654.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $654.6 million (up 9.21% YoY) and the FY2025 annual result came in at $643.4 million, up 18.33% from the prior year.
• Retained Earnings rose to $654.6 million in Q2 2026 per CORT's latest filing, from $611.6 million in the prior quarter.
• Over five years, Retained Earnings peaked at $738.5 million in Q4 2023 and troughed at $217.8 million in Q1 2022.
• A 5-year average of $489.6 million and a median of $528.4 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 105.59% in 2022, then declined 26.37% in 2024.
• Over 5 years, Retained Earnings stood at $662.3 million in 2022, then gained by 11.5% to $738.5 million in 2023, then slipped by 26.37% to $543.7 million in 2024, then rose by 18.33% to $643.4 million in 2025, then rose by 1.74% to $654.6 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $654.6 million, $611.6 million, and $643.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.